FLONASE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLONASE (FLONASE).
Fluticasone propionate is a corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators such as cytokines, leukotrienes, and prostaglandins, thereby reducing nasal inflammation.
| Metabolism | Primarily metabolized by CYP3A4 in the liver; extensive first-pass metabolism via hydrolysis to an inactive metabolite. |
| Excretion | Primarily hepatic metabolism (CYP3A4), with metabolites excreted in feces (approximately 87-90%) and urine (<5% unchanged). Less than 5% of a dose is excreted renally as unchanged drug. |
| Half-life | Terminal elimination half-life is approximately 3 hours (range 2-4 hours). This short half-life supports twice-daily dosing for systemic effects; however, intranasal administration achieves local therapeutic concentrations with minimal systemic exposure. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 4.2 L/kg (range 3.7-5.0 L/kg), indicating extensive tissue distribution. This high Vd suggests wide distribution into peripheral tissues. |
| Bioavailability | Intranasal: Systemic bioavailability is less than 2% due to extensive first-pass metabolism. Oral: Approximately 1-2% due to first-pass metabolism; not available as oral formulation. No IV formulation available. |
| Onset of Action | Intranasal: Symptom relief begins within 12 hours, with maximum benefit observed after several days of regular use. Not effective for immediate relief of acute symptoms. |
| Duration of Action | Duration of action is approximately 24 hours after achieving steady-state (typically after 3-4 days of twice-daily dosing). Clinical effect is sustained with regular use; intermittent dosing may not maintain efficacy. |
| Molecular Weight | 500.57 |
2 sprays (50 mcg/spray) per nostril once daily; may increase to 2 sprays per nostril twice daily if needed. Intranasal route.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Children 4-11 years: 1 spray (50 mcg) per nostril once daily; Children 12 years and older: same as adult. |
| Geriatric use | No specific dose adjustment; use with caution due to potential increased systemic exposure. |
| 1st trimester | Data limited; intranasal corticosteroids are generally considered low risk. No evidence of teratogenicity in animal studies. Use if benefit outweighs risk. |
| 2nd trimester | No specific concerns; systemic absorption minimal. Preferred for allergic rhinitis when needed. |
| 3rd trimester | No specific concerns; minimal systemic absorption. Avoid high doses due to theoretical risk of fetal adrenal suppression. |
Clinical note
Comprehensive clinical and safety monograph for FLONASE (FLONASE).
| Placental transfer | Fluticasone propionate is highly protein-bound (91%) and has low lipophilicity; minimal placental transfer expected. Animal studies show no significant fetal exposure at therapeutic doses. |
| Breastfeeding | Fluticasone propionate (Flonase) is minimally excreted into breast milk due to low oral bioavailability and high protein binding. Intranasal administration results in negligible systemic levels. Considered compatible with breastfeeding; observe for potential effects on lactation or infant adrenal function with prolonged high-dose use. |
■ FDA Black Box Warning
None
| Serious Effects |
Untreated nasal mucosal infection (e.g., herpes simplex, candidiasis)Recent nasal trauma or surgery (until healing complete)Hypersensitivity to fluticasone propionate or any excipient
| Precautions | May cause nasal septal perforation or epistaxis, Risk of adrenal suppression with prolonged high-dose use, Caution in patients with recent nasal mucosal trauma or surgery, Avoid in patients with untreated local infections |
| Food/Dietary | No significant food interactions. Grapefruit juice does not affect fluticasone propionate nasal spray. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L2 - Safer |
| Teratogenic Risk | Fluticasone propionate, the active ingredient in FLONASE, is classified as FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic at high systemic doses. However, the intranasal route results in minimal systemic absorption. For first trimester, the risk is considered low but not zero based on epidemiological data. Second and third trimester use is generally safe, but caution is advised as systemic corticosteroids may increase risk of maternal hypertension and gestational diabetes. Overall, fluticasone propionate is preferred over oral corticosteroids for asthma/allergic rhinitis during pregnancy. |
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond routine prenatal care. However, if high doses are used or if the patient is using other corticosteroids, monitor for signs of adrenal suppression, maternal hypertension, or hyperglycemia. In asthmatic patients, monitor asthma control and fetal growth if systemic corticosteroids are also used. |
| Fertility Effects | There are no known adverse effects of intranasal fluticasone on human fertility. Animal studies did not show impairment of fertility at doses several times the maximum human daily intranasal dose. However, systemic corticosteroids may affect ovulation; this is unlikely with intranasal administration due to low systemic absorption. |
| For optimal efficacy, instruct patients to prime the spray by releasing 4 actuations into the air before first use or after >7 days of non-use. Administer intranasally; tilt head slightly forward, insert nozzle into nostril pointing away from septum, and sniff gently while actuating. Avoid spraying directly onto nasal septum to reduce risk of epistaxis. Onset of action is 12 hours, but maximal benefit may require 3-5 days of daily use. Not effective for immediate relief of nasal congestion due to acute inflammation; consider short-term decongestant spray if needed. Tapering not required on discontinuation. Monitor for nasal ulceration, candidiasis, or symptoms of HPA axis suppression at high doses or prolonged use. |
| Patient Advice | Do not use for sudden relief of nasal stuffiness; it works best when used regularly as directed. · Do not exceed the recommended dosage unless instructed by your doctor. · Rinse the spray tip with hot water (but not dried) and replace cap after each use. · Discard the bottle after 120 sprays (marked on label) even if not empty to ensure correct dosing. · Avoid contact with eyes. If spraying occurs in eyes, flush with water for 10 minutes. · Common side effects include nosebleeds, nasal burning or irritation, headache, and sore throat. · Do not use if you have an untreated nasal infection or recent nasal surgery/injury. · Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. |